Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling - Université Paris Cité Access content directly
Journal Articles Nature Cell Biology Year : 2021

Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling

Jasmin Post
  • Function : Author
Julian Buissant Des Amorie
  • Function : Author
Dimitrios Laskaris
  • Function : Author
Ravian van Ineveld
  • Function : Author
Simone Kersten
  • Function : Author
Andrea Bertotti
  • Function : Author
Francesco Sassi
  • Function : Author
Benjamin Cappe
Sander Mertens
  • Function : Author
Ingrid Verlaan-Klink
  • Function : Author
Sylvia Boj
  • Function : Author
Rob Vries
  • Function : Author
Holger Rehmann
  • Function : Author
Peter Vandenabeele
Franck Riquet
  • Function : Author
Livio Trusolino
  • Function : Author
Johannes Bos
  • Function : Author
Hugo Snippert
  • Function : Author

Abstract

Direct targeting of the downstream mitogen-activated protein kinase (MAPK) pathway to suppress extracellular-regulated kinase (ERK) activation in KRAS and BRAF mutant colorectal cancer (CRC) has proven clinically unsuccessful, but promising results have been obtained with combination therapies including epidermal growth factor receptor (EGFR) inhibition. To elucidate the interplay between EGF signalling and ERK activation in tumours, we used patient-derived organoids (PDOs) from KRAS and BRAF mutant CRCs. PDOs resemble in vivo tumours, model treatment response and are compatible with live-cell microscopy. We established real-time, quantitative drug response assessment in PDOs with single-cell resolution, using our improved fluorescence resonance energy transfer (FRET)-based ERK biosensor EKAREN5. We show that oncogene-driven signalling is strikingly limited without EGFR activity and insufficient to sustain full proliferative potential. In PDOs and in vivo, upstream EGFR activity rigorously amplifies signal transduction efficiency in KRAS or BRAF mutant MAPK pathways. Our data provide a mechanistic understanding of the effectivity of EGFR inhibitors within combination therapies against KRAS and BRAF mutant CRC.

Dates and versions

hal-03255726 , version 1 (09-06-2021)

Identifiers

Cite

Bas Ponsioen, Jasmin Post, Julian Buissant Des Amorie, Dimitrios Laskaris, Ravian van Ineveld, et al.. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling. Nature Cell Biology, 2021, 23 (4), pp.377-390. ⟨10.1038/s41556-021-00654-5⟩. ⟨hal-03255726⟩
196 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More